Drug and Alcohol Testing Collison IL

DOT 300x183 Our local DOT drug and alcohol testing centers are located in Collison IL and the surrounding areas providing DOT drug testing, DOT alcohol testing and DOT physicals for all DOT modes regulated by Part 40. Same day service is available at our Collison IL DOT drug testing facilities and most of our DOT drug testing locations are within minutes of your home or office.

What type of DOT Testing is required?

Coastal Drug Testing provides DOT pre-employment, random, post-accident, reasonable suspicion and return to duty testing at our Collison IL DOT drug testing centers.

If you hold a CDL license, a large, medium or a small trucking company, Coastal Drug Testing has a complete DOT compliance package which includes all the requirements to comply with CFR 49 part 40.

All Coastal Drug Testing DOT drug testing centers utilize SAMHSA Certified laboratories and a licensed Medical Review Officer as required by DOT part 40 regulations.

The U.S Department of Transportation (DOT) requires that all DOT regulated "safety sensitive" employees have a negative DOT pre-employment drug test result on file and be actively enrolled in a DOT approved random drug and alcohol random testing pool (consortium).

In addition, if a DOT regulated company has more than one "safety sensitive" employee, the employer must also have a written DOT drug and alcohol policy along with an on-site supervisor that must have completed a reasonable suspicion supervisor training program.

On the road and need a DOT Drug or Alcohol test? No Worries!

To be compliant with DOT regulations, a company's DOT drug and alcohol testing program must have the following components:

Employee Drug Testing
Written Drug and Alcohol Policy
Supervisor Training
Substance Abuse Referral
Employee Education
Random Selection Program
Post Accident Testing
Designated Employer Representative
Federal Chain of Custody Forms
Part 40 Regulations on File

The Department of Transportation (DOT) has specific drug and alcohol testing requirements for the all transportation modes all DOT agencies.

Our modes included are:

Federal Motor Carrier Safety Administration (FMCSA)
Federal Aviation Administration (FAA)
Federal Transit Administration (FTA)
United States Coast Guard (USCG)
Pipeline and Hazardous Materials Safety Administration (PHMSA)
Federal Railroad Administration (FRA)

Are You Enrolled in a DOT Consortium?

Individuals who are employed in a position designated as "safety sensitive" must be actively enrolled in a random drug and alcohol testing program. Oftentimes, covered employees will join a group of other DOT regulated employees in a random testing program and this is referred to as a DOT Consortium. Generally, an employer who has less than fifty employees or single operators will join the consortium which will comply with the random drug and alcohol testing requirements of 49 CFR Part 40. Employers that have over 50 employees who are regulated by Part 40 may elect to be enrolled in a "stand alone" random testing pool.

The DOT consortium is cost effective and complies with all requirements of 49 CFR Part 40 which mandates that all "safety sensitive" employees be enrolled in a random drug and alcohol testing program.

The Department of Transportation (DOT) has strict regulations requiring regulated companies and independent operators (CDL License Holders) to be an active member of a DOT drug and alcohol Consortium and failure to comply with these regulations can result in significant fines and other DOT sanctions.

We are fully versed in the DOT procedures for pre-employment drug testing, random drug testing, reasonable suspicion drug testing, post-accident drug testing, return to duty drug testing and follow up drug testing.

Local Area Info: Interleukin 35

IL-35 is a dimeric protein composed of IL-12? and IL-27? chains, which are encoded by two separate genes called IL12A and EBI3, respectively. IL-35 receptor consists of IL-12R?2 (part of the IL-12R) and gp130 (part of IL-27R) chains. Compared to these two related interleukins, IL-35 is also able to signal through only one of the aforementioned chains. This was proven in vivo when absence of either of the receptor chains did not influence effects of IL-35.

Secreted by regulatory T-cells (Tregs), regulatory B-cells (Bregs) or even CD8+ regulatory T cells, IL-35 suppresses inflammatory responses of immune cells. IL-35 is not constitutively expressed in tissues, but the gene encoding IL-35 is transcribed by vascular endothelial cells, smooth muscle cells and monocytes after activation with proinflammatory stimuli. IL-35 has selective activities on different T-cell subsets; it induces proliferation of Treg cell populations but reduces activity of Th17 cell populations.

Studies in mice show the absence of either IL-35 chain from regulatory Tregs reduces the cells' ability to suppress inflammation. This has been observed during cell culture experiments and using an experimental model for inflammatory bowel disease. A group of scientists established a CIA (collagen-induced arthritis) mouse model to show suppressive effects of IL-35. Intraperitoneal injection of IL-35 in the tested subjects lowered expression of several factors linked to this disease (such as VEGF and its receptors, TNF-?). The effect of IL-35 in this case seems to be the inhibition of STAT1 signalling pathway. Another experiment performed on a mouse model of EAE has shown, that mice lacking IL-35-producing B cells are unable to recover from the T-cell mediated demyelination but are resistant to infection by pathogenic intracellular microbe Salmonella typhimurium.

Related Regional Locations

(800) 828-7086